About this trial
Gastroparesis is a burdensome condition that is caused by abnormal motor function of the stomach that results in delayed gastric emptying. It typically manifests with bloating, nausea, vomiting, abdominal pain, and even excessive weight loss and dehydration. The most common causes of gastroparesis are idiopathic, diabetic, medication-induced or iatrogenic (postsurgical) gastroparesis.
Implantation of a gastric neurostimulation device is a surgical option to improve gastric emptying in patients with medication-refractory gastroparesis. Enterra® system is a gastric electrical stimulation that sends mild pulses through leads implanted in the stomach wall that stimulate gastric smooth muscles and nerves in order to improve symptoms and quality of life.
Aim of the investogators' registry trial is to evaluate the feasibility and efficacy of laparoscopic gastric pacemaker implantation for electrical stimulation (Enterra® system). Primary endpoints of the study are symptom severity, health-related quality of life, and frequency of hospitalization before and after pacemaker implantation, perioperative complication rate, and cost effectiveness.
Eligibility criteria
Qualifiers
Scintigraphically proven gastroparesis
Failed conservative therapy
Severe impairment of quality of life
Written informed consent
Disqualifiers
Age < 18 years
Prior gastric resection
Trial design
Treatments tested in this trial
- Gastric pacemaker (Enterra system) implantation
Treatment groups
Locations
1Sponsors and collaborators
Evangelic Hospital Kalk Cologne
Lead sponsor
University of Cologne
Sponsor institution
Enterra Medical, Inc.
Collaborator